The challenges of innovative therapeutic interventions in hemophilia
Louis M. Aledort

An update on UCL/St Jude Haemophilia studies; successes and obstacles ahead
Amit Nathwani

Acquired TTP: are we ready for a prognosis-dependent management?
Paul Coppo

Hemolytic uremic syndrome (HUS)
Massimo Cugno

The most recent advances in aHUS and TTP including complement and VWFcomplement interactions.
Giuseppe Remuzzi, Marina Noris

Randomisation or real world data?
Frits R. Rosendaal, Leiden, The Netherlands

Von Willebrand factor
Cecile Denis

Collagen and VWF interactions and beyond
Veronica Flood, Robert R. Montgomery

The genetics of von Willebrand disease, to include recent developments from ourselves and others.
Anne C. Goodeve

The potential use of nanobodies in the treatment of VWD and hemophilia
Peter J. Lenting

Determinants of FVIII inhibitor risk: Is VWF a key factor?
David P. Lillicrap

VWF regulation of blood vessel formation and function
Anna M. Randi

Old concepts and new functions of von Willebrand factor: 2017
Zaverio M. Ruggeri

Emerging concepts in acquired thrombotic thrombocytopenic purpura
Karen Vanhoorelbeke

Endocytosis of factor FVIII by antigen-presenting cells: roles of von Willebrand factor and complement
Sebastien Lacroix-Desmazes, Paris, France

Differential diagnosis of thrombotic microangiopathies
Jeffrey C. Laurence, New York, USA  

Immune recognition of ADAMTS13 in acquired TTP
Jan Voorberg, Amsterdam, The Netherlands

Mechanism of thrombotic microangiopathy: lesson from zebrafish to men
X. Long Zheng, Birmingham, USA

… more preliminary topics soon on line, stay tuned!